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Abstract
Background: Neutrophil influx is an important sign of hyperacute neuroinflammation, whereas the entry of
activated lymphocytes into the brain parenchyma is a hallmark of chronic inflammatory processes, as observed in
multiple sclerosis (MS) and its animal models of experimental autoimmune encephalomyelitis (EAE). Clinically
approved or experimental therapies for neuroinflammation act by blocking leukocyte penetration of the blood
brain barrier. However, in view of unsatisfactory results and severe side effects, complementary therapies are
needed. We have examined the effect of chlorite-oxidized oxyamylose (COAM), a potent antiviral polycarboxylic
acid on EAE.
Methods: EAE was induced in SJL/J mice by immunization with spinal cord homogenate (SCH) or in IFN-γ-deficient
BALB/c (KO) mice with myelin oligodendrocyte glycoprotein peptide (MOG35-55). Mice were treated intraperitoneally
(i.p.) with COAM or saline at different time points after immunization. Clinical disease and histopathology were
compared between both groups. IFN expression was analyzed in COAM-treated MEF cell cultures and in sera and
peritoneal fluids of COAM-treated animals by quantitative PCR, ELISA and a bioassay on L929 cells. Populations of
immune cell subsets in the periphery and the central nervous system (CNS) were quantified at different stages of
disease development by flow cytometry and differential cell count analysis. Expression levels of selected chemokine
genes in the CNS were determined by quantitative PCR.
Results: We discovered that COAM (2 mg i.p. per mouse on days 0 and 7) protects significantly against hyperacute
SCH-induced EAE in SJL/J mice and MOG35-55-induced EAE in IFN-γ KO mice. COAM deviated leukocyte trafficking
from the CNS into the periphery. In the CNS, COAM reduced four-fold the expression levels of the neutrophil CXC
chemokines KC/CXCL1 and MIP-2/CXCL2. Whereas the effects of COAM on circulating blood and splenic leukocytes
were limited, significant alterations were observed at the COAM injection site.
Conclusions: These results demonstrate novel actions of COAM as an anti-inflammatory agent with beneficial
effects on EAE through cell deviation. Sequestration of leukocytes in the non-CNS periphery or draining of
leukocytes out of the CNS with the use of the chemokine system may thus complement existing treatment
options for acute and chronic neuroinflammatory diseases.
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Background
Neuroinflammation is a common denominator in a wide
variety of diseases of the central nervous system (CNS),
ranging from various forms of acute infectious or vascu-
lar meningoencephalitis to chronic inflammation asso-
ciated with multiple sclerosis (MS) or neurodegenerative
diseases. Hyperacute experimental autoimmune enceph-
alomyelitis (EAE), henceforth named as such to distin-
guish it from T cell-mediated forms of EAE, is induced
by immunization of mice with spinal cord homogenates,
has an important neutrophil component [1] and is an
appropriate model for the study of neuroinflammation
in acute encephalitis. By contrast, chronic forms of EAE
are often induced with CNS peptide antigens or by
adoptive transfer of neuroantigen-specific T cell clones
or T cells from sensitized animals, and are widely used
to study disease mechanisms and new therapeutic
approaches for MS [2].
Various aspects of recent research point to a role of
the blood–brain barrier (BBB) as a crucial structure to
prevent neuroinflammation [3,4]. Neuroinflammation
occurs upon migration of leukocytes through the endo-
thelial and parenchymal layers of the BBB in order to
gain access to the CNS parenchyma [5] and as a result
of chemokine-governed attraction of specific leukocytes
to the CNS [6]. Current ways to prevent leukocyte entry
into the CNS include treatment with IFN-α/β or anti-
adhesive agents that prevent binding of leukocytes to
CNS endothelium [7,8].
IFN-β has been proven effective for the treatment of
relapsing remitting MS [7]: IFN-β decreases the relapse
rate, ameliorates disease activity and reduces the number
of inflammatory CNS lesions [9]. Many studies have
shown that IFN-β exerts beneficial effects on the devel-
opment of EAE and on the stability of the BBB [10-12].
Therefore, induction of endogenous IFN-β is an alterna-
tive approach to substitution therapy with IFN-β. In
early studies, such stimulation was typically achieved by
induction of IFN-β with viral double-stranded RNAs or
therapeutically by polyanions, including polyI:C and
polyacrylates [13,14]. PolyI:C has been reported to sup-
press disease in a murine model of relapsing EAE by
inducing endogenous IFN-β but has high toxicity [15].
Chlorite-oxidized oxyamylose (COAM), a synthetic poly-
anion with a therapeutic index of 300 to 500, is a potent
antiviral agent [16], which we recently showed to result
in almost complete protection against acute infection
with the neurotropic mengovirus. Similarly, COAM has
no cytotoxic effects in vitro [17,18]. In this animal model
of infection, COAM was shown to induce myeloid cell
chemotaxis, in part through binding and activity of the
chemokine granulocyte chemotactic protein-2/CXCL6
[19]. In view of the supposed IFN-inducing capacity of
COAM, we started a series of studies to determine its
effects in EAE models. COAM was shown to suppress
neuroinflammation significantly by interfering with the
chemokine system and by causing retention of immune
cells at the peritoneal injection site, thus affecting cell
fluxes to the brain. These results suggest that diverting
leukocyte chemotaxis from the brain into the non-CNS
periphery may represent a novel and pharmacologically
attainable treatment option that complements existing
therapies for various forms of acute neuroinflammation.
Methods
Mice
SJL/J and IFN-γ KO mice were bred under conventional
conditions in the Experimental Animal Breeding Facility
of the University of Leuven, Belgium. The generation
and basic characterization of IFN-γ-deficient mice of the
129 x BALB/c strain have been described previously
[20]. These mice were backcrossed for eight generations
to the parental BALB/c strain. EAE experiments were
carried out with 8 to 10 week old male and female mice.
During the experiments, mice were kept under con-
ventional housing conditions. They received a regular
diet and acidified drinking water without antibiotics. All
procedures were conducted in accordance with pro-
tocols approved by the local Ethics Committee (Licence
number LA1210243, Belgium).
Reagents
Mycobacterium tuberculosis strain H37Ra, Incomplete
Freund’s Adjuvant (IFA) and Complete Freund’s Adju-
vant (CFA) were purchased from Difco Laboratories
(Detroit, MI, USA). Pertussis toxin was purchased from
List Biological Laboratories (Campbell, CA, USA).
COAM was prepared as described [21]. It was free of
endotoxin (<13.3 pg/mg COAM, assayed in the Limulus
amoebocyte lysate assay) and devoid of contaminating
proteins (assayed by protein staining) [18]. Myelin oligo-
dendrocyte glycoprotein peptide (MOG35-55) was pro-
duced by Fmoc (fluorenylmethoxycarbonyl) solid phase
peptide synthesis, purified by reversed phase chromatog-
raphy and peptide mass was confirmed by electrospray
ion trap mass spectrometry [22].
Induction and clinical evaluation of EAE and treatment
with COAM
For induction of hyperacute EAE in SJL/J mice, an emul-
sion was prepared consisting of 100 mg/ml of lyophi-
lized SJL/J mouse spinal cord homogenate (SCH) in PBS
and 4 mg/ml M. tuberculosis (strain H37Ra) in CFA.
Chronic EAE was induced in IFN-γ KO BALB/c mice by
injecting 50 μg of MOG35-55 peptide (1 mg/ml in saline)
emulsified in IFA containing 4 mg/ml of M. tuberculosis.
On day 0, mice were injected subcutaneously in each of
the two hind footpads with 50 μl of the emulsion.
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Immediately thereafter and on day 2, 100 ng of pertussis
toxin in 50 μl saline was intravenously (i.v.) administered
in the tail vein. Animals were anaesthetized for injections.
Mice were evaluated daily for signs of clinical disease.
Disease severity was recorded as follows: grade 0, nor-
mal; grade 0.5, floppy tail; grade 1, tail paralysis and mild
impaired righting reflex; grade 2, mild hind limb weak-
ness and impaired righting reflex; grade 3, moderate to
severe hind limb paresis and/or mild forelimb weakness;
grade 4, complete hind limb paralysis and/or moderate
to severe forelimb weakness; grade 5, quadriplegia or
moribund; grade 6, death.
COAM is hydrophilic and was dissolved in pyrogen-
free 0.9% NaCl. Mice were treated with an intraperito-
neal (i.p.) injection of COAM (2 mg in 0.2 ml 0.9%
NaCl) on days 0 and/or 7 after EAE immunization.
Control mice received an equivalent volume of saline
(0.9% NaCl).
Isolation and induction of mouse embryonic cells
Mouse embryonic fibroblasts (MEF) were isolated from
SJL/J mouse embryos around 17 days of gestation. The
uterine horns were dissected and placed in a petri dish
containing MEM (Invitrogen, Paisly, Scotland) supple-
mented with penicillin (500 U/ml; Continental Pharma,
Brussels, Belgium) and streptomycin (500 μg/ml; Con-
tinental Pharma). Each embryo was separated from its
placenta and surrounding membranes and washed three
times with MEM. Subsequent procedures were accord-
ing to standard conditions: incubation of embryo frag-
ments in 50 ml trypsin-ethylenediaminetetraacetic acid
(EDTA), centrifugation of cell suspension at 135 g for 15
minutes, two washings of the cell pellets with MEM
growth medium containing 10% heat-inactivated FCS,
200 mM L-glutamine and 0.1% sodium bicarbonate
(Invitrogen) and culture of adherent cells to confluency
in growth medium in flat-bottomed flasks (75 cm2, TPP,
Zurich, Switzerland) for four days.
For the induction of IFN-β in MEF, 1 x 106 cells in a
total volume of 2 ml growth medium were seeded in six-
well plates (TPP). After incubation for 24 hours, cells
were stimulated with different concentrations of COAM
in MEM with 2% FCS for 72 hours. Supernatants were
collected for detection of IFN-β with a biological anti-
viral assay on IFN-sensitive fibroblastoid L929 cells and
with ELISA for IFN-γ determination. The MEF cells were
harvested after 72 hours and used for quantitative PCR
(qPCR) analysis of cytokine and chemokine mRNAs.
Relative quantitation of cytokine, chemokine and
chemokine receptor mRNAs by qPCR
Total RNA was purified from cells or tissues (RNeasy
Mini Kit, Qiagen, Venlo, The Netherlands) and tran-
scribed into cDNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA). qPCR reactions were carried out in an
ABI Prism 7000 Sequence Detection System (Applied
Biosystems) in a total volume of 30 μl, containing 50 ng
of extracted RNA, 15 μl of TaqMan Gene Expression
Master Mix (Applied Biosystems) and 1.5 μl of primer/
probe mix for the appropriate cytokine, chemokine or
chemokine receptor (TaqMan Gene Expression Inven-
toried Assays, Applied Biosystems). The qPCR condi-
tions consisted of an initial step at 50°C for 2 minutes,
an activation step at 95°C for 10 minutes followed by 40
cycles of 15 seconds at 95°C and 1 minute at 60°C. 18S
or glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Applied Biosystems) were included as endogenous refer-
ence genes for normalization of target mRNA transcripts.
The fold change in gene expression normalized to the en-
dogenous reference and relative to the untreated control
was determined according to the comparative ΔΔCt
method [23].
Bioassay on L929 cells for detection of IFN activity
IFN assays were carried out as described [24]. Briefly,
mouse L929 cells were seeded in flat-bottom 96-well
plates at a density of 6 x 104 cells per well in MEM
growth medium. In each assay a laboratory mouse IFN
standard (consisting of mouse L929 cell-derived IFN-αβ,
induced with Newcastle disease virus) was included and
0.5 log10 dilutions of the samples were made in growth
medium. After 24 hours of incubation at 37°C, the cul-
tures were challenged with 50 μl of mengovirus (multi-
plicity of infection, 0.01 plaque-forming units per cell).
Cell controls received growth medium only. Plates were
incubated at 37°C for 24 hours and cells were colored
with crystal violet. The detection limit of this biological
IFN assay was 3.16 units/ml.
Detection of cytokines and chemokines by ELISA
Mouse IFN-γ concentrations were determined by the
sandwich ELISA described previously [25]. Briefly, sam-
ples were incubated in microtiter plates coated with
mouse anti-rat IFN-γ-specific mAb as capturing antibody
(DB1; gift from Dr. P. van der Meide, Cytokine Biology
Unit, Central Laboratory Animal Institute, Utrecht Uni-
versity, Utrecht, The Netherlands). The bound cytokine
was detected by incubation in turn with rat anti-mouse
IFN-γ-specific mAb (F1), used as primary detection anti-
body, and goat anti-rat immunoglobulin-peroxidase
conjugate (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) as secondary detection antibody.
IFN-β protein concentrations in sera of IFN-γ KO
mice were quantified using the VeriKine Mouse Inter-
feron Beta ELISA kit (PBL InterferonSource, Piscataway,
NJ, USA). GCP-2 was detected by an ELISA developed
in our laboratory, as described [26]. IL-17, KC and
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MIP-2 levels were measured by sandwich ELISA using
paired antibodies according to the manufacturer’s recom-
mendations (DuoSet ELISA Development System, R&D
Systems, Abingdon, UK).
Cell preparation from various organs
Brain and spinal cord
Mice were sacrificed and gently perfused through the left
cardiac ventricle with 50 ml ice-cold PBS to eliminate
intravascular contaminating blood cells in the CNS.
Spinal cords were removed by flushing the spinal col-
umn with sterile PBS and brains were dissected. Both
tissues were homogenized and filtered through a cell
strainer (Becton Dickinson Labware, Franklin Lakes, NJ,
USA). After centrifugation (10 minutes, 300 g), the cells
were resuspended in 40% Percoll and underlayed with
72% Percoll. The gradient was centrifuged at 500 g for
20 minutes at 10°C. Before staining analysis, the inter-
phase cells were collected and extensively washed in
PBS supplemented with 2% FCS.
Blood
Peripheral blood samples were taken at the orbital sinus,
using heparin as an anticoagulant. Leukocytes were
obtained by lysis of red blood cells by two incubations
(5 and 3 minutes, 37°C) in NH4Cl solution (0.83% w/v
in 0.01M Tris/HCl; pH 7.2). Remaining cells were
washed two times with ice-cold PBS, supplemented with
2% FCS, and then analyzed.
Spleen
Spleens were isolated, cut into small pieces and passed
through cell strainers, to obtain single cell suspensions.
Red blood cells were lysed by two incubations (5 and 3
minutes at 37°C) of the splenocyte suspension in NH4Cl
solution (0.83% w/v in 0.01M Tris/HCl; pH 7.2).
Remaining cells were washed two times with ice-cold
PBS containing 2% FCS.
Peritoneal fluid
Peritoneal lavage fluid was collected following killing of
the mice. Five ml of ice-cold PBS containing 2% FCS
was injected i.p. and the abdominal space was gently
massaged. The lavage fluid was collected and centrifuged
at 300 g for 10 minutes.
Flow cytometry analysis
Single cell suspensions (0.5 x 106 cells) were incubated
for 15 minutes with the Fc-receptor-blocking antibodies
anti-CD16/anti-CD32 (BD Biosciences Pharmingen, San
Diego, CA, USA), washed with PBS supplemented with
2% FCS and then stained for 30 minutes with the indi-
cated fluorescein isothiocyanate (FITC)-conjugated and
phycoerythrin (PE)-conjugated antibodies. Cells were
washed twice and fixed with 0.37% formaldehyde in PBS.
FITC-conjugated anti-CD8, PE-conjugated anti-CD4,
FITC-conjugated anti-CD11b, PE-conjugated anti-Gr-1
and PE-conjugated anti-F4/80 were purchased from
eBioscience (San Diego, CA, USA). Cells were analyzed
by a FACSCalibur flow cytometer and data were pro-
cessed with the CellQuest software (Becton Dickinson).
Differential cell counting and histopathology analysis
Cells from spinal cord and brain and from other ana-
tomical compartments were applied to slides by centrifu-
gation at a density of approximately 105 cells/slide using
a Shandon Cytospin 2. Cytospin preparations were
stained with Hemacolor (Merck, Darmstadt, Germany)
and leukocytes were identified on the basis of morph-
ology. Five series of 100 cells from each slide were
counted and the results were expressed as a percentage
of the total cell count.
Spinal cords and brains were fixed in 4% formalin.
Four micron thick paraffin sections were stained with
H & E and scored for signs of neuroinflammation by
two independent observers.
Statistical analyses
Differences in the clinical course of EAE were analyzed
by Wilcoxon’s non-parametric test or, where appropriate,
by the Chi-square test with Yates’ correction. Significant
differences between groups were evaluated using a non-
parametric Mann Whitney test. All P values of 0.05 or
less were considered significant.
Results
COAM protects against hyperacute and chronic EAE
without inducing interferon-β
Monophasic hyperacute EAE in SJL/J mice was induced
by immunization with syngeneic SCH in CFA and mice
were treated by injection of COAM (2 mg i.p.) at various
time points. Control mice consisted of EAE-induced ani-
mals treated with excipiens and untreated naive mice
were used to measure background levels of all para-
meters. The first signs of hyperacute EAE appeared
between days 11 and 13 after immunization. Mice
treated with a single dose of COAM on the day of
immunization (day 0) had significantly less severe clin-
ical signs at day 14 (P < 0.05; indicated by single asterisk
in Figure 1, panel A) and decreased incidence of the
disease to 50% (P <0.05) (Figure 1A, Table 1) compared
to saline-treated control animals. These results indicate
that a single injection of COAM results in effects that
last several days. By contrast, a single i.p. injection of
COAM on day 8 after immunization was ineffective in
this animal model (Table 1). Mice treated with COAM
on days 0 and 7 after immunization exhibited a stronger
reduction of hyperacute EAE compared to those treated
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with a single dose of COAM at day 0 (Figure 1A and
1B), with significantly reduced severity of clinical signs
and mortality rates (P <0.05 and P <0.01, respectively)
compared to saline–treated mice (90% mortality)
(Table 1). These in vivo results indicated that two i.p.
injections of COAM at days 0 and 7 after immunization
provided partial protection against SCH-induced hypera-
cute EAE and this significantly decreased the mean daily
disease score from the onset of clinical signs until the
termination of the experiment at day 40. This effect was
dose-dependent (with decreased survival rates after
treatment with 0.5 mg per mouse).
In order to validate these data in other EAE models,
we tested COAM in antigen-specific EAE using
immunization of IFN-γ KO BALB/c mice with MOG35-
55 peptide and a treatment schedule with COAM on
days 0 and 7. Figure 2 shows the cumulated results of
three independent experiments. These demonstrated
that COAM (mean maximal disease score: 2.37 ± 0.47;
incidence: 11/15; mean day of disease onset: 17.55 ± 1.0)
protected significantly against MOG peptide-induced
EAE in comparison with control animals (mean maximal
disease score: 4.27 ± 0.29; incidence: 13/13; mean day of
onset: 17.31 ± 1.16).
After administration of COAM or other polyanions in
viral infection models, low levels of IFN are detectable
in the serum during the first 24 to 48 hours, with peak
IFN levels after 18 hours [16]. However, more recent
antiviral studies have suggested that COAM does not
induce IFN-β in vitro [18] or in vivo [19]. Hence, it is
not clear whether COAM can induce IFN or whether
virus challenge is the main inducer of IFN. To distin-
guish between these possibilities it is necessary to exam-
ine whether COAM can induce IFN-β in virus-free
conditions. Therefore, we tested extensively whether
IFN-β which protects against EAE [11], is upregulated in
COAM-treated hyperacute EAE animals or cell cultures.
First, groups of SJL/J mice induced for EAE were bled
6, 18 and 24 hours after each COAM administration
(2 mg i.p. on days 0 and 7 after immunization). Sera
were tested for IFN bio-activity on L929 cells with the
use of a viral cytopathogenic reduction assay. This anal-
ysis revealed no IFN-like activity (detection limit <3.16
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Figure 1 The clinical course of hyperacute EAE in COAM-treated mice. (A) SJL/J mice were immunized subcutaneously with syngeneic SCH
for induction of hyperacute EAE and treated i.p. at day 0 with 2 mg COAM. Mean disease scores were calculated for COAM-treated (n = 10,
filled squares) or saline-treated (n = 10, open squares) animals. One significant data point is indicated by an asterisk at day 14. (B) When two
injections with COAM were given on days 0 and 7 after immunization, significant reduction of disease scores (asterisks) were observed from day
12 onwards. The clinical course of hyperacute EAE in these mice is shown as mean daily group score ± SEM. Dead animals were scored grade 6
from the day of death until the end of the study. Black vertical arrows indicate time points of COAM administration. * P <0.05 for comparison
with saline-treated group (Wilcoxon test). COAM, chlorite-oxidized oxyamylose; EAE, experimental autoimmune encephalomyelitis; SCH, spinal
cord homogenate; SEM, standard error of the mean.
Table 1 Hyperacute EAE development in SJL/J mice treated with COAM
Day 0 Day 8 Day 0 + 7
saline COAM saline COAM saline COAM
Mean maximum disease score ± SEM 5.6 ± 0.25 3.8 ± 0.78* 3.6 ± 0.75 4.6 ± 0.62 5.75 ± 0.24 2.72 ± 0.79*
Incidence 10/10 5/10* 8/10 9/10 10/10 6/9
Mortality 8/10 5/10 4/10 6/10 9/10 2/9**
Mean day of onset ± SEM 12.3 ± 0.2 13.1 ± 0.37 13 ± 0.56 12.2 ± 0.14 11.8 ± 0.28 12.8 ± 0.37
SJL/J mice were immunized subcutaneously with syngeneic SCH for induction of EAE as described in Materials and Methods. They were treated i.p. with 2 mg
COAM or saline on the indicated days after immunization. Dead animals were scored 6 from the day of death until the end of the study. * P <0.05; ** P <0.01 for
comparison with saline-treated group; Wilcoxon test (disease score) or Chi-square test (incidence and mortality). COAM, chlorite-oxidized oxyamylose; EAE,
experimental autoimmune encephalomyelitis; SCH, spinal cord homogenate; SEM, standard error of the mean.
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IFN-α/β preparations yielded the expected titers between
2.0 to 2.5 log10 units/ml. In addition, no IFN-γ was de-
tectable by a specific ELISA in any of the titrated sera
samples (detection level was 1.25 units/ml). Similarly,
peritoneal fluids from saline- and COAM-treated EAE
mice, collected at days 5, 9 and 16 after immunization,
did not contain any IFN-like activity. Sera from EAE-
induced IFN-γ KO mice (collected at 0, 6, 18 and
24 hours after each COAM injection) were tested in an
IFN-β ELISA (PBL Interferon Source). All samples were
below the detection limit of 15.6 pg/ml, ruling out the
possibility that the observed reduction in EAE with
COAM in these mice is due to high IFN-β levels.
In a second set of experiments, we tested whether
COAM could induce the production of IFN-β in pri-
mary SJL/J mouse embryonic cell cultures. Mixtures of
fibroblasts, endothelial and epithelial cells were stimu-
lated with different concentrations of COAM (1, 10, 30,
100, 300, 1,000 μg/ml) for 24, 48 or 72 hours, and IFN-β
mRNA levels were measured in cell extracts using
qPCR, revealing only marginal background levels of
IFN-β mRNA and no differences between the different
time points or concentrations of COAM (Table 2). Also
a biological assay with L929 cells revealed no IFN-like
activity in the supernatants of these cultures (<3.16
units/ml), despite detectable antiviral activity in samples
containing 100 μg/ml or higher concentrations of
COAM (titers between 1.0 to 1.5 log10 units/ml). This
was equivalent to the effect of 1,000 μg/ml of COAM
directly administered to the L929 cells and was thus
explained as antiviral COAM carry-over on these test
cells [18]. To test whether IFN-β induction took place at
an earlier time point, mouse embryonic cell cultures
were incubated with COAM (100, 1,000 μg/ml) for 4, 8
and 16 hours. Again, addition of COAM did not result
in an increase of IFN-β mRNA copies (Table 2), nor in
measurable titers of IFN-like bioactivity (<3.16 units/ml).
Hence, COAM significantly diminished SCH-induced
hyperacute EAE, but did not induce IFN. Therefore,
alternative molecular and cellular mechanisms for the
protective effects of COAM against EAE were examined.
COAM reduces cell infiltration into the CNS
A prominent feature in chronic neuroinflammation is
cell infiltration into the cerebrospinal fluid and CNS par-
enchyma. Infiltrates consist mainly of mononuclear cells
(monocytes, dendritic cells, natural killer cells, CD4+
and CD8+ lymphocytes) [2]. In hyperacute EAE models,
as the one used here, CNS neutrophils increase consid-
erably [1]. To test whether inflammatory myeloid cell
numbers were altered in the CNS of i.p. COAM-treated
animals versus control saline-treated animals we isolated
spinal cords and brain tissues during early and late
stages of hyperacute EAE and analyzed these by flow
cytometry. A cytometry staining pattern with indication
of the percentages of CD11b+Gr-1+ cells, representative
for data obtained in four experiments, is shown in
Figure 3A. Following EAE induction, an increase in the
number of neutrophils isolated from spinal cords and
brains by day 16 after immunization was striking. We
observed that neutrophil infiltration in the spinal cords
and brains of COAM-treated mice was not different
before onset of disease (day 5 and 9 after immuniza-
tion, data not shown) compared with the control group
receiving saline. During the acute phase of disease (day
16 after immunization; saline-treated mice selected with
disease scores = 3.5, COAM-treated mice selected with
disease scores = 4) a substantially smaller CD11b+Gr-1+
population was observed in the CNS of the COAM-treated
group, as illustrated for one experiment (Figure 3B).
When the results of four independent experiments were
pooled, a lower percentage of CD11b+Gr-1+ cells in the
spinal cord (21.76 ± 5.09%; P <0.05) of COAM-treated
(mean disease score: 2.64) versus saline-treated animals
(39.41 ± 5.03% and 16.75 ± 5.27% for spinal cord and
brain respectively; mean disease score = 2.17) with symp-
toms of EAE (day 14 to 16) was observed. No overt dif-
ferences in the populations of macrophages (CD11b+F4/
80+ cells), CD4+ and CD8+ cells between both groups
were detected (data not shown). By investigation of
cytospin slides, we obtained data in accordance with the
FACS results. Histological examination of longitudinal
sections of the entire spinal cord and different brain sec-
tions obtained from mice with signs of EAE revealed



























Figure 2 COAM reduces MOG peptide-induced EAE. IFN-γ KO
BALB/c mice were immunized with MOG35-55 and the test
group was given 2 mg COAM/mouse i.p. at days 0 and 7 after
immunization, whereas the control group received excipiens. EAE
clinical scores were recorded daily. Dead animals were scored 6
from the day of death until the end of the experiment. * P <0.05;
** P <0.01 for comparison with saline-treated group (Wilcoxon test,
control n = 13, COAM n = 15). COAM, chlorite-oxidized oxyamylose;
EAE, experimental autoimmune encephalomyelitis; MOG, myelin
oligodendrocyte glycoprotein.
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reduced meningeal inflammation and numbers as well as
sizes of perivascular infiltrates (Figure 4). These com-
bined data demonstrated that COAM reduced absolute
and relative numbers of trafficking neutrophils into the
CNS (based on the flow cytometric data) and inhibited
neuroinflammation and hyperacute EAE symptoms as
seen by histopathology analysis and clinical evaluations.
COAM alters expression of inflammatory chemokines and
their receptors in the CNS of hyperacute EAE mice
As COAM dampened clinical hyperacute EAE signs and
local cellular signs of CNS neuroinflammation, we inves-
tigated the mRNA expression pattern of inflammatory
chemokines in the CNS of naive, saline-treated and
COAM-treated hyperacute EAE animals. At day 11 or
12 post immunization, that is, a time point when clinical
disease became apparent in saline-treated hyperacute
EAE mice, brains and spinal cords were analyzed for
expression of the neutrophil chemokines KC/CXCL1,
MIP-2/CXCL2 and GCP-2/CXCL6, of chemoattractants
predominant for monocytes and activated T cells (MCP-
1/CCL2, MIP-1α/CCL3 and RANTES/CCL5) as well as
of IP-10/CXCL10, which is specific for activated T cells.
In EAE-induced mice, both saline-treated as well as
COAM-treated, mRNA levels for all these chemokines,
except for GCP-2/CXCL6, were significantly upregulated
in brains as well as in spinal cords, compared to levels in
naive control mice (Figure 5). Compared to saline-
treated EAE-induced animals, treatment with COAM
resulted in significant decreases of KC, MIP-2 and
RANTES in CNS tissues. Specifically, the brain content
of mRNAs encoding KC decreased significantly after
Table 2 COAM does not induce IFN-β
Incubation time COAM (μg/ml)
1 10 30 100 300 1,000 control
4 hours ND ND ND 1.17 ± 0.20 ND 0.91 ± 0.31 1.00 ± 0.12
8 hours ND ND ND 1.33 ± 0.35 ND 1.07 ± 0.11 1.00 ±0.1
16 hours ND ND ND 0.98 ± 0.18 ND 1.62 ± 0.46 1.00 ± 0.25
24 hours 1.12 ± 0.13 0.90 ± 0.15 0.19 ± 0.06 0.69 ± 0.37 0.17 ± 0.03 1.32 ± 0.65 1.00 ± 0.29
48 hours 1.11 ± 0.19 0.52 ± 0.09 1.92 ± 0.05 1.44 ± 0.25 1.55 ± 0.66 0.65 ± 0.39 1.00 ± 0.22
72 hours 1.28 ± 0.26 0.47 ± 0.14 1.43 ± 0.06 1.38 ± 0.38 1.5 ± 0.62 1.86 ± 0.59 1.00 ± 0.41
Primary SJL/J mouse embryonic cells were incubated with different concentrations of COAM (1 to 1,000 μg/ml) for various time intervals. After the indicated
incubation period, cells were lysed and total cellular RNA was subjected to qPCR. IFN-β mRNA expression levels were measured and normalized against untreated
controls. Data represent mean values of fold IFN-β mRNA level ± SEM of two independent experiments (n=2-4). COAM, chlorite-oxidized oxyamylose; ND = not
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B Spinal cord
Brain
Figure 3 Decreased numbers of neutrophils in the spinal cord and brain of COAM-treated mice. (A) Flow cytometry analysis for the
indicated markers was used to identify leukocytes isolated from the spinal cord and brain. In this experiment cells were isolated on day 16 after
immunization and stained for CD11b and Gr-1. Numbers indicated on each graph represent the percentages of CD11b+Gr-1+ and CD11b+Gr-1-
cells. Each plot represents a staining pattern of pooled cells from three mice of one out of four representative experiments. (B) Morphologic
examination of spinal cord and brain cytospin preparations stained with Hemacolor on day 16 after immunization after treatment with COAM.
Bars represent averages ± SEM of at least three analyses; numbers of analyses are indicated between brackets; in each experiment cells from
two mice were pooled per group. COAM, chlorite-oxidized oxyamylose; SEM, standard error of the mean.
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COAM treatment (decrease of median by 4.7 fold, P
<0.05) and MIP-2 mRNA showed a trend towards de-
crease (P = 0.0774). In spinal cords, chemokine mRNA
levels followed a decreasing course for IP-10 (P =
0.0535), MIP-1α and MCP-1. For the neutrophil chemo-
kines KC and MIP-2, mRNA expression levels after
COAM treatment were significantly decreased in spinal
cords (decrease of median by 4.6 fold (P <0.01) and 17.7
fold (P <0.05), respectively), compared to saline-treated
hyperacute EAE mice. The spinal cords from COAM-
treated hyperacute EAE animals also exhibited signifi-
cantly reduced expression levels of RANTES mRNA
(decrease of median by 3.6 fold, P <0.05). The mRNA
levels of GCP-2 remained unchanged in spinal cords and
brains after treatment of hyperacute EAE mice with
COAM. In conclusion, the expression of specific chemo-
kines for neutrophils and other leukocyte types was
decreased in the CNS by COAM.
In order to further characterize the CNS chemokine
milieu associated with reduced disease symptoms in
COAM-treated mice, we determined the expression
levels of specific chemokine receptors by qPCR analysis.
CXCR1 and CXCR2 are the most relevant chemokine
receptors of neutrophils. CXCR2 is the receptor of MIP-
2 and KC, whereas GCP-2 acts on both receptors
CXCR1 and CXCR2. CCR4 and CX3CR1 play important
roles in regulating the traffic of peripheral leukocytes to
the inflamed CNS [27,28]. During onset of clinical dis-
ease (day 11 to 12 after immunization) CXCR1, CXCR2
and CCR4 mRNA levels in the brain and spinal cord
were significantly increased compared to naive control
mice (Figure 6). We detected significantly lower expres-
sion levels of CXCR1 and CXCR2 in COAM-treated
mice than in saline controls. mRNA levels for CXCR1
and CXCR2 declined significantly in the spinal cords
after the administration of COAM (decrease of median
by 5.1 fold (P = 0.031) and 8.5 fold (P = 0.033),
respectively), whereas the mRNA changes for CCR4
were not significantly different between COAM-treated
and control mice. The mRNA levels of CX3CR1
remained unchanged in spinal cords and brains after
treatment of hyperacute EAE mice with COAM. To-
gether, these data showed that COAM downregulated
the expression of chemokine receptors mediating chemo-
tactic activity of neutrophils, but had no effect on the
regulation of CNS CCR4 expression.
Effects of COAM on blood cells and splenocytes
To investigate whether COAM caused changes in
leukocyte numbers in anatomical compartments other
than the CNS, blood cells and splenocytes were isolated
on days 5, 9 and 14 to 16 after immunization and ana-
lyzed by flow cytometry. Immunization for hyperacute
EAE induced a significant increase in the number of
neutrophils (ranging between 15% to 30%) in the circula-
tion compared to non-immunized mice (5%), in accord-
ance with previous observations [29,30]. In mice treated










Figure 4 Histological analysis of spinal cord and brain sections after treatment with EAE. Spinal cords and brains from COAM- (n = 2)
and saline-treated EAE animals (n = 2) were isolated during acute disease (day 17 after immunization) and fixed in 4% formol. Four micron thick
paraffin sections were stained with H & E. Scale bars represent 100 μm. In the control sections, black arrows indicate prominent leukocyte
infiltrations and at the surface perimeningeal leukocytes are visible. After treatment with COAM the numbers and sizes of these infiltrations were
reduced. COAM, chlorite-oxidized oxyamylose; EAE, experimental autoimmune encephalomyelitis.
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Figure 5 Inflammatory chemokine expression in the CNS of hyperacute EAE control and COAM-treated mice. Mice were injected i.p.
with a dose of 2 mg of COAM on day 0 and 7 after induction of EAE. CNS cells were harvested on day 11 or 12 post immunization. Fold mRNA
levels of the CXC chemokines (A) KC, (B) MIP-2, (C) GCP-2 and (D) IP-10, and of the CC chemokines (E) MCP-1, (F) MIP-1α and (G) RANTES were
determined by qPCR. Histograms and dots indicate, respectively, group medians and range of individual data points (for each cohort the number
of mice (n) exceeded 10, 13≤n≤18). Differences between COAM-treated EAE mice, untreated EAE controls and naive mice were statistically
analyzed by the Mann Whitney test. Alterations in control hyperacute EAE mice or COAM-treated hyperacute EAE mice versus naive mice
are indicated on top of every cohort. Pairwise significant comparisons between saline-treated control and COAM-treated hyperacute EAE
mice are indicated by horizontal lines above the compared groups. * P <0.05; ** P <0.01; *** P <0.001. CNS, central nervous system; COAM,
chlorite-oxidized oxyamylose; EAE, experimental autoimmune encephalomyelitis.
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observed in the circulation than in naive mice, with only
a significant difference between saline and COAM at
day nine after immunization (P <0.05) (Figure 7A). No
significant differences in the percentages of circulating
monocytes were observed between naive, saline-treated
and COAM-treated EAE animals (Figure 7B). Spleen
cells of immunized COAM-treated and saline-treated
mice contained about equal percentages of neutrophils
and macrophages (data not shown), whereas a decrease
in the number of CD4+ (Figure 7C) and CD8+
(Figure 7D) splenocytes was observed after treatment
with COAM, with significant differences at days five and
nine after immunization.
COAM drastically alters leukocyte populations at the
injection site
Finally, the effects of COAM on leukocyte populations
at the injection site were studied. Mice were induced for
hyperacute EAE, treated i.p. with 2 mg COAM on days
0 and 7 after immunization with SCH and sacrificed
at different time points after immunization. Peritoneal
lavage fluids were collected for morphologic examin-
ation on day 5, that is, the preclinical phase; day 9, that
is, shortly before the expected onset of clinical symp-
toms of hyperacute EAE; and on days 14, 15 or 16,
which corresponded with the peak of disease. Diseased
mice were selected so that their mean clinical scores
were comparable between COAM- and saline-treated
groups. Peritoneal cells were cytospun onto slides,
stained with Hemacolor, and leukocyte subsets were
counted. Naive and saline-treated hyperacute EAE mice
on day 5 after immunization yielded 1.47 to 1.93 x 106
cells/ml, comprising high numbers of macrophages
(65.13% and 54.89% of total cells, respectively) and a
small proportion of neutrophils (0.4% and 0.58% for
naive and saline-treated hyperacute EAE mice, respect-
ively). COAM induced a peritoneal leukocyte influx nine
days after EAE induction (P <0.05 versus saline control).
Macrophages (Figure 8A) and particularly neutrophils
(Figure 8B) were found to be significantly increased in
COAM-treated mice. These data are in line with previ-
ous findings in a virus infection model [19]. These
effects of COAM were detectable in hyperacute EAE
animals even on day 14, one week after the last COAM
injection on day 7. FACS analyses reinforced these cytos-























































































































Figure 6 Chemokine receptor expression in the CNS of hyperacute EAE control and COAM-treated mice. SJL/J mice were immunized
with SCH in CFA and were administered i.p. injections of COAM on days 0 and 7. Brain and spinal cord tissue were isolated on day 11 or 12 post
immunization. mRNA expression of chemokine receptors (A) CXCR1, (B) CXCR2, (C) CCR4 and (D) CX3CR1 were analyzed by qPCR. Histograms
and dots indicate, respectively, group medians and range of individual data points (for each cohort 13≤n≤18). * P <0.05; *** P <0.001 compared
to naive mice as determined by the Mann Whitney test. Pairwise significant comparisons between saline-treated and COAM-treated hyperacute
EAE mice are indicated by horizontal lines. CNS, central nervous system; COAM, chlorite-oxidized oxyamylose; EAE, experimental autoimmune
encephalomyelitis; SCH, spinal cord homogenate.
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contained an excessive proportion of CD11b+Gr-1+ cells
compared with saline-treated mice on each of the exam-
ined days (Figure 8C). When the numbers of CD11b
+Gr-1+ cells from three independent experiments were
expressed as percentages of total cell numbers collected
per mouse, peritoneal fluids of hyperacute EAE-induced
COAM-treated mice were shown to contain approxi-
mately four times higher numbers of neutrophils than
those of saline-treated hyperacute EAE mice. For the
analysis of defined lymphocyte subtypes in animals trea-
ted with COAM, peritoneal fluid cells were stained with
anti-CD4-PE and anti-CD8-FITC antibodies. COAM
injection in immunized mice significantly increased the
percentage of peritoneal CD4+ and CD8+ cell numbers
as compared to saline-treated EAE mice (Figure 8D and
E). With the use of in vivo imaging, we could demon-
strate that i.p. injected labeled COAM remained mainly
in the peritoneal cavity for prolonged time intervals,
whereas it disappeared quickly from the mice after intra-
venous injection (data not shown).
Mouse CXC chemokines that are known to specifically
attract neutrophils include GCP-2, KC and MIP-2 [31].
We studied whether these chemokines are induced in
the peritoneum of EAE-immunized mice in response to
COAM. Indeed, GCP-2 was present in the peritoneal
lavage fluid 24 hours after the first COAM injection,
whereas GCP-2 was barely detectable in saline-treated
control mice (Figure 9A). Induction of EAE caused an
upregulation of KC expression (Figure 9B) and protein
levels of GCP-2 and KC were found to be significantly
increased over saline controls at 24 hours, 48 hours, day
5 and day 9 after COAM administration. Levels of MIP-
2 expression and of the cytokine IL-17 were below the
detection limits. Hence, induction of GCP-2 and KC
by COAM may constitute a chemotactic force for
mobilization of neutrophils, and this favors the proposal
of retention of immune cells at the COAM-injection
site, rather than of increased cell proliferation.
In conclusion, COAM induced significant leukocyte
recruitment at the peripheral injection site. Specifically,
neutrophils as fast contributors to hyperacute neuroin-
flammation and also monocytes and lymphocytes as
slower effector cells in acute inflammatory reactions
were recruited to the periphery by COAM injection.
Discussion
The present study provides a novel approach with thera-
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Figure 7 Leukocytes in blood and spleen in response to COAM during hyperacute EAE. Mice were immunized for hyperacute EAE and
administered 2 mg COAM i.p. on days 0 and 7. Blood cells and splenocytes were collected on days 5, 9 and 14 to 16 after immunization. (A)
Blood cells were stained with anti-CD11b-FITC and anti-Gr-1-PE and this analysis demonstrated COAM-induced transient blood neutrophilia at day
nine in hyperacute EAE-induced mice. (B) Macrophages in the circulation were assessed by FACS analysis with anti-F4/80-PE and anti-CD11b-FITC.
(C) COAM induced a decrease in the number of spleen CD4+ lymphocytes on days five and nine. (D) CD8+ splenocytes were identified with
anti-CD8-FITC. (A-D) The data were combined from three independent experiments. Bars indicate the means ± SEM of three to nine mice.
* P <0.05; ** P <0.01 for comparison with naive mice; Mann Whitney test. Pairwise comparisons between saline- and COAM-treated hyperacute
EAE mice are indicated above the histograms. COAM, chlorite-oxidized oxyamylose; EAE, experimental autoimmune encephalomyelitis; FITC,
fluorescein isothiocyanate; PE, phycoerythrin; SEM, standard error of the mean.
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inflammation, namely by deviation of leukocyte traffick-
ing from the CNS to peripheral body compartments.
Furthermore, we provide an example of a pharmaco-
logical agent to attain this goal in vivo. Two rationales
prompted us to evaluate COAM in EAE: (i) the sugges-
tion [16] that COAM induces endogenous IFN-β with
known therapeutic effects in MS and EAE and (ii) the
fact that COAM protected against immunopathologies
observed in acute lethal virus infection models [17,19].
Our data provide no evidence for the first possibility and
stimulated research into alternative explanations of
mechanisms of action. Indeed, by a number of experi-
mental approaches, including IFN bioassays, ELISAs and
mRNA titrations in hyperacute EAE animals and on
MEF cell cultures, we corroborated and extended recent
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Figure 8 COAM induces peritoneal alterations in leukocyte populations in animals with hyperacute EAE. Peritoneal cells were collected
on days 0, 5, 9 and 14, 15 or 16 post immunization with SCH in SJL/J mice. (A) The percentages (morphologic examinations) of peritoneal
macrophages and (B) neutrophils in the peritoneal exudates were compared between naive mice and EAE-induced mice, treated i.p. with
saline or with COAM. Data are compiled from three experiments; bars represent averages ± SEM of three to nine mice. Statistical significance
was determined using the Mann Whitney test. (C-E) Flow cytometric analysis of leukocytes in the peritoneal cavity of COAM-treated versus
saline-treated EAE mice. Cells were stained for the presence of CD11b, Gr-1, CD4 and CD8. (C) Example of FACS analysis with indication of gating
of double positive cells. The numbers within the gates indicate the percentages of Gr-1-positive cells present in the whole sorted peritoneal
lavages. One representative analysis out of nine is shown. (D-E) The data of three experiments were pooled and the percentages of CD4+ and
CD8+ cells on each of the examined days are shown. Bars represent averages ± SEM, the individual numbers of animals (n) for each condition
are indicated below each of the histograms. Asterisks indicate * P <0.05; ** P <0.01 for comparison with naive mice (Mann Whitney test).
Pairwise comparisons (P values) between saline- (control) and COAM-treated hyperacute EAE mice are indicated on top of the histograms.
COAM, chlorite-oxidized oxyamylose; EAE, experimental autoimmune encephalomyelitis; SCH, spinal cord homogenate; SEM, standard error
of the mean.
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in vivo, but instead affects the chemokine system. Our
present data are in line with findings in infection and
tumor animal models [18,19,32].
One effect of COAM in the CNS is the reduction of
KC/CXCL1 expression in brain and spinal cord and of
MIP-2/CXCL2 and RANTES/CCL5 expression in the
spinal cord. Reduction of specific chemokine expression
levels may contribute to the observed significantly
reduced leukocyte counts in the CNS. After treatment
with COAM, reduced neuroinflammation was paralleled
by significant reduction in hyperacute EAE disease
scores. Further analyses were done to determine how
COAM may affect trafficking of inflammatory cells.
COAM treatment increased circulating and peritoneal
neutrophil counts, in line with less influx into the CNS
and compartmental deviation of neutrophils out of the
CNS towards the COAM injection site. The latter was
also observed in another study [19], in which it was
found that i.p. COAM bound GCP-2/CXCL6 leading to
enhanced chemotaxis of myeloid cells into the peritoneal
cavity. The present study thus provides a practical
example for the thesis that modulation of the chemokine
system may be exploited therapeutically to reduce
leukocyte infiltration into the CNS. Blocking of chemo-
kine activity by binding to glycosaminoglycans (GAGs)
was proposed as an anti-inflammatory modus [33,34].
However, with COAM a different action of GAG mim-
icry is proposed: one that does not block but instead
enhances chemokine activities in specific body compart-
ments. Collectively, our findings lead to the suggestion
that at the injection site COAM captures endogenous
chemokines from the environment and creates a potent
chemotactic gradient and thus lures inflammatory cells
from the whole body into a specific compartment.
Furthermore, these findings are complemented by the
fact that COAM reduces CNS expression of specific che-
mokines with significant reduction of leukocytes in the
CNS. We coined the term ‘cell deviation therapy’ for
this concept.
Another way to decrease CNS infiltration by leuko-
cytes is with the adhesion inhibitor Natalizumab/
Tysabri, but this treatment increases the risk of polyo-
mavirus infections [35-37]. COAM, being an immuno-
modulating agent with potent antiviral activity, might be
an alternative treatment option for patients infected with
such viruses, but this remains to be proven. Finally, the
combination of COAM and Tysabri with complemen-
tary modes of therapeutic and antiviral actions constitu-
tes another future approach to combat various forms
of neuroinflammation.
Conclusions
Treatment of SCH-induced hyperacute neutrophilic
EAE in SJL/J mice and of MOG-peptide-induced EAE in
IFN-γ-deficient BALB/c mice with COAM resulted in
significant amelioration of disease symptoms. This study
provides a novel mechanism and an interesting molecu-
lar probe to study leukocyte deviation. Our data might
have implications for the treatment of inflammatory and
autoimmune diseases such as EAE and MS.
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Figure 9 GCP-2 and KC are upregulated in the peritoneum in
response to COAM. SJL/J mice were induced for EAE by injection
with SCH and treated with COAM (2 mg i.p., day 0 and 7 post
immunization) or a control solution of saline. At different time points
after COAM injection, peritoneal fluid was collected by i.p. lavage.
Protein levels of GCP-2 and KC in peritoneal fluids were detected
by ELISA. The total number (n) of mice examined per group are
indicated between brackets; histograms indicate group means ±
SEM. Compared to the naive levels, significant P-values of (*) P <0.05
were obtained (Mann–Whitney test). Pairwise comparisons between
saline- and COAM-treated hyperacute EAE mice are indicated above
the histograms. GCP-2 and KC levels in all naive mice (without EAE
induction) were below the detection limit. COAM, chlorite-oxidized
oxyamylose; EAE, experimental autoimmune encephalomyelitis;
SCH, spinal cord homogenate; SEM, standard error of the mean.
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